Cargando…

Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease

N-Palmitoylethanolamide (PEA) is a non-endocannabinoid lipid mediator belonging to the class of the N-acylethanolamine phospolipids and was firstly isolated from soy lecithin, egg yolk, and peanut meal. Either preclinical or clinical studies indicate that PEA is potentially useful in a wide range of...

Descripción completa

Detalles Bibliográficos
Autores principales: Beggiato, Sarah, Tomasini, Maria Cristina, Ferraro, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667638/
https://www.ncbi.nlm.nih.gov/pubmed/31396087
http://dx.doi.org/10.3389/fphar.2019.00821
_version_ 1783440066248441856
author Beggiato, Sarah
Tomasini, Maria Cristina
Ferraro, Luca
author_facet Beggiato, Sarah
Tomasini, Maria Cristina
Ferraro, Luca
author_sort Beggiato, Sarah
collection PubMed
description N-Palmitoylethanolamide (PEA) is a non-endocannabinoid lipid mediator belonging to the class of the N-acylethanolamine phospolipids and was firstly isolated from soy lecithin, egg yolk, and peanut meal. Either preclinical or clinical studies indicate that PEA is potentially useful in a wide range of therapeutic areas, including eczema, pain, and neurodegeneration. PEA-containing products are already licensed for use in humans as a nutraceutical, a food supplement, or a food for medical purposes, depending on the country. PEA is especially used in humans for its analgesic and anti-inflammatory properties and has demonstrated high safety and tolerability. Several preclinical in vitro and in vivo studies have proven that PEA can induce its biological effects by acting on several molecular targets in both central and peripheral nervous systems. These multiple mechanisms of action clearly differentiate PEA from classic anti-inflammatory drugs and are attributed to the compound that has quite unique anti(neuro)inflammatory properties. According to this view, preclinical studies indicate that PEA, especially in micronized or ultramicronized forms (i.e., formulations that maximize PEA bioavailability and efficacy), could be a potential therapeutic agent for the effective treatment of different pathologies characterized by neurodegeneration, (neuro)inflammation, and pain. In particular, the potential neuroprotective effects of PEA have been demonstrated in several experimental models of Alzheimer’s disease. Interestingly, a single-photon emission computed tomography (SPECT) case study reported that a mild cognitive impairment (MCI) patient, treated for 9 months with ultramicronized-PEA/luteolin, presented an improvement of cognitive performances. In the present review, we summarized the current preclinical and clinical evidence of PEA as a possible therapeutic agent in Alzheimer’s disease. The possible PEA neuroprotective mechanism(s) of action is also described.
format Online
Article
Text
id pubmed-6667638
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66676382019-08-08 Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease Beggiato, Sarah Tomasini, Maria Cristina Ferraro, Luca Front Pharmacol Pharmacology N-Palmitoylethanolamide (PEA) is a non-endocannabinoid lipid mediator belonging to the class of the N-acylethanolamine phospolipids and was firstly isolated from soy lecithin, egg yolk, and peanut meal. Either preclinical or clinical studies indicate that PEA is potentially useful in a wide range of therapeutic areas, including eczema, pain, and neurodegeneration. PEA-containing products are already licensed for use in humans as a nutraceutical, a food supplement, or a food for medical purposes, depending on the country. PEA is especially used in humans for its analgesic and anti-inflammatory properties and has demonstrated high safety and tolerability. Several preclinical in vitro and in vivo studies have proven that PEA can induce its biological effects by acting on several molecular targets in both central and peripheral nervous systems. These multiple mechanisms of action clearly differentiate PEA from classic anti-inflammatory drugs and are attributed to the compound that has quite unique anti(neuro)inflammatory properties. According to this view, preclinical studies indicate that PEA, especially in micronized or ultramicronized forms (i.e., formulations that maximize PEA bioavailability and efficacy), could be a potential therapeutic agent for the effective treatment of different pathologies characterized by neurodegeneration, (neuro)inflammation, and pain. In particular, the potential neuroprotective effects of PEA have been demonstrated in several experimental models of Alzheimer’s disease. Interestingly, a single-photon emission computed tomography (SPECT) case study reported that a mild cognitive impairment (MCI) patient, treated for 9 months with ultramicronized-PEA/luteolin, presented an improvement of cognitive performances. In the present review, we summarized the current preclinical and clinical evidence of PEA as a possible therapeutic agent in Alzheimer’s disease. The possible PEA neuroprotective mechanism(s) of action is also described. Frontiers Media S.A. 2019-07-24 /pmc/articles/PMC6667638/ /pubmed/31396087 http://dx.doi.org/10.3389/fphar.2019.00821 Text en Copyright © 2019 Beggiato, Tomasini and Ferraro http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Beggiato, Sarah
Tomasini, Maria Cristina
Ferraro, Luca
Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
title Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
title_full Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
title_fullStr Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
title_full_unstemmed Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
title_short Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
title_sort palmitoylethanolamide (pea) as a potential therapeutic agent in alzheimer’s disease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667638/
https://www.ncbi.nlm.nih.gov/pubmed/31396087
http://dx.doi.org/10.3389/fphar.2019.00821
work_keys_str_mv AT beggiatosarah palmitoylethanolamidepeaasapotentialtherapeuticagentinalzheimersdisease
AT tomasinimariacristina palmitoylethanolamidepeaasapotentialtherapeuticagentinalzheimersdisease
AT ferraroluca palmitoylethanolamidepeaasapotentialtherapeuticagentinalzheimersdisease